Compare BBLG & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBLG | NXTS |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | Israel |
| Employees | 2 | 9 |
| Industry | Industrial Specialties | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 4.3M |
| IPO Year | N/A | N/A |
| Metric | BBLG | NXTS |
|---|---|---|
| Price | $1.32 | $5.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.2K | ★ 24.1K |
| Earning Date | 05-13-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $0.55 |
| 52 Week High | $5.98 | $6.21 |
| Indicator | BBLG | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 60.28 |
| Support Level | $1.30 | $0.66 |
| Resistance Level | $1.36 | $5.31 |
| Average True Range (ATR) | 0.05 | 0.61 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 18.06 | 38.44 |
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.